Showing 3721-3730 of 5154 results for "".
- Aesthetics Biomedical's Vivace Ultra Wins FDA Clearancehttps://practicaldermatology.com/news/aesthetics-biomedicals-vivace-ultra/2461390/The FDA has given the nod to Aesthetics Biomedical Inc.’s Vivace Ultra for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. An innovative reimagination and technical upgrade of the legacy Vivace Microneedle RF device, the Vivace Ultra comb
- Study: Psoriasis Does Not Appear to Increase Heart Attack Risk in People with Significant Kidney Diseasehttps://practicaldermatology.com/news/study-psoriasis-does-not-appear-to-increase-heart-attack-risk-in-people-with-significant-kidney-disease/2461387/Studies have suggested that psoriasis is an independent risk factor for heart attack in the general population, but investigators recently found that in people who also have end-stage renal disease, which shares many risk factors with heart disease, it is not. “There are a lot of
- Hugel Resubmits Botulax BLA to FDAhttps://practicaldermatology.com/news/hugel-resubmits-botulax-bla-to-fda-1/2461380/Hugel resubmitted the BLA for its botulinum toxin called Botulax for smoothing glabellar lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) to advance into the U.S. market i
- Industry Vet Curtis Cluff Named President and CFO of BioPhotas Inc.https://practicaldermatology.com/news/industry-vet-curtis-cluff-named-president-and-cfo-of-biophotas-inc/2461378/Curtis Cluff is the new President and Chief Financial Officer BioPhotas Inc., manufacturers of the Celluma series of light therapy devices. In this newly created role, Mr. Cluff will report to Patrick Johnson, Chief Executive Officer and inventor of the Celluma. &quo
- Study: Galderma's RelabotulinumtoxinA Earns High Marks from Patientshttps://practicaldermatology.com/news/study-galdermas-relabotulinumtoxina-earns-high-marks-from-patients/2461377/Galderma's investigational ready-to-use liquid botulinum toxin RelabotulinumtoxinA scored high patient satisfaction and psychological well-being ratings for the treatment of glabellar lines and lateral canthal lines in addition to previously reported safety and efficacy, according to pre
- Galderma Debuts Sensitive Skincare Facultyhttps://practicaldermatology.com/news/galderma-debuts-sensitive-skincare-faculty/2461372/Reinforcing its commitment to advancing dermatology for every skin story, Galderma has formed a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives. The Faculty will focus on three key pillars of research, innovation, and engagem
- Candesant Biomedical Introduces New SweatTech Initiative at ASDShttps://practicaldermatology.com/news/candesant-biomedical-novel-investigational-technology-for-hyperhydrosis/2461371/Candesant Biomedical is introducing a new initiative – SweatTech™ – at the ASDS annual meeting. The company is also developing a new novel technology (currently under FDA review) that reduces axillary hyperhidrosis. Their “TAT” (targeted alkali thermolysis) pat
- Business News: Incyte Buys Startup Villarishttps://practicaldermatology.com/news/business-news-incyte-buys-startup-villaris/2461370/Incyte will pay $70 million upfront to buy Villaris Therapeutics, a startup working on an experimental drug for vitiligo. Villaris’ lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023. Villaris&
- BeautyHealth Introduces Hydrafacial x JLo Beauty Boosterhttps://practicaldermatology.com/news/beautyhealth-introduces-the-hydrafacial-x-jlo-beauty-booster/2461369/The BeautyHealth Company is rolling out the Hydrafacial x JLo Beauty Booster . “I'm so excited to partner with Hydrafacial to create the new JLo Beauty Booster,” says founder of JLo Beauty Jennifer Lopez in a news release. “Hydrafacial is one of my favorite treatme
- DermTech Presents on Value of Decentralization of Clinical Trialshttps://practicaldermatology.com/news/dermtech-presents-on-value-of-decentralization-of-clinical-trials/2461368/Technology can help decentralize clinical trials, leading to greater patient satisfaction, a more diverse patient population, better retention and cost savings, according to a presentation by DermTech at Outsourcing in Clinical Trials Southern California, held from Sept. 28-29 in San Di